<DOC>
	<DOCNO>NCT01888367</DOCNO>
	<brief_summary>This randomize , blind , placebo standard care control study efficacy novel antibiotic contain gel compare placebo gel prevent surgical site infection abdominal surgery . patient randomize active placebo gel double-blind manner . The gel apply single time incision closure end surgery . A cohort patient also randomize standard care , saline irrigation prior skin closure , open manner . The efficacy , safety tolerability active gel assess compare control group ( combine placebo gel standard care group ) . Patients randomize DFA-02 active gel : placebo gel : standard care 4:1:1 ratio .</brief_summary>
	<brief_title>Safety , Efficacy Tolerability Study 20 mL DFA-02 Patients Undergoing Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Surgical Wound Infection</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Males females 18 year age old ; 2 . If female , subject must postmenopausal , surgically sterilize , childbearing potential , must negative serum urine pregnancy test within 48 hour surgery agree use adequate birth control study 30 day administration study agent ; 3 . Body mass index ( BMI ) â‰¥ 20 ; 4 . Scheduled undergo nonemergent abdominal surgery involve plan incision 7 cm great ; 5 . Willing able give inform consent ; 6 . Available evaluation Baseline final evaluation 30 day postsurgery . 1 . Known hypersensitivity gentamicin , vancomycin , aminoglycoside antibiotic excipients study product ; 2 . Emergency surgery ; 3 . Significant concomitant surgical procedure ; 4 . Prior laparotomy within last 60 day plan procedure ; 5 . Planned second laparotomy abdominal surgical procedure within 30 day plan first procedure ; 6 . Expectation surgical drain place incision ; 7 . Preoperative sepsis , severe sepsis , septic shock ; 8 . Abdominal wall infection/surgical site infection previous laparotomy/laparoscopy reason ; 9 . Active systemic infection systemic ( oral intravenous ) antibiotic therapy within 1 week prior date surgery specify preoperative antimicrobial prophylaxis ; 10 . Requirement gentamicin vancomycin preoperative antimicrobial prophylaxis ; 11 . Concurrent systemic use potentially neurotoxic , nephrotoxic , and/or ototoxic drug ; 12 . Preoperative evaluation suggest intraabdominal process might preclude full closure skin ; 13 . Ongoing treatment ( e.g . chemotherapy , radiation ) noncolorectal cancer ; 14 . History significant drug alcohol abuse ; 15 . Serum Creatinine &gt; 1.8 mg/dL ; 16 . Serum Bilirubin &gt; 2.5 time upper limit normal ; 17 . Subjects immunocompromised include limited systemic corticosteroid use chemotherapy/radiation 30 day prior surgery , organ transplantation , HIV infection ; 18 . Known history HIV ; 19 . Pregnant lactating , childbearing potential practice birth control method high degree reliability ; 20 . Refusal accept medically indicate blood product ; 21 . Participation within 30 day start study experimental drug device study , currently participate study administration investigational drug device within 60 day anticipate ; 22 . Unable participate study reason opinion Principal Investigator ; 23 . Postsurgical life expectancy le 30 day ; 24 . Expected discharge hospital le 3 day surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>